Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 30 May 2019 Planned End Date changed from 1 Feb 2023 to 28 Feb 2023.
- 30 May 2019 Planned primary completion date changed from 1 Feb 2022 to 28 Feb 2022.
- 27 Feb 2018 New trial record